Everest Medicines Announces Interim Results for First Half of 2025

Everest Medicines Announces Interim Results for First Half of 2025

SHANGHAI, Aug. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025…

Everest trims loss, pipeline eyes Phase III

SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 along with a corporate update. "In the first half of 2025, Everest Medicines accelerated its transformation into a leading global biopharmaceutical compa…

Hua Medicine Announces 2025 Interim Results – EastMud

Open the article to view the coverage from eastmud.com